Biotech stocks have tumbled in recent months and years. For example, the SPDR S&P Biotech ETF (NYSE:XBI) has sunk 40% so far this year. As a result, there are many oversold biotech stocks for investors to buy. But in the next six months, two main factors should push the sector much higher. Here are three oversold biotech stocks that are…
Biotech stocks are often seen as a segment of the market that has the potential to thrive regardless of the broader stock market sentiment. Essentially, biotech companies are high-risk, high-reward investments. This is because each stage of progress can be a catalyst for the stocks. A positive outcome can change the fortune of the company. But, a negative one could…
As we move into the rest of 2022, it seems that biotech stocks could continue to be a viable play in the stock market. This can be attributed to the ongoing coronavirus concerns fueling the booming industry. Now, as the Omicron variant sweeps the globe, it shouldn’t come as a surprise as many investors continue to look out for the…
Biotech ETFs offer diversified, low-cost exposure. If anyone didn’t already understand the dynamic potential of the health care sector, the pandemic has proven in real time how innovative the next generation of pharmaceutical companies are – and how vital they are to public health. So-called “biotechnology” companies look beyond chemical compounds or surgical tools to harness the power of biological systems…
“In a world where interest rates are so low and uncertainty seems to be the norm, baby boomers need to look for stable dividend stocks that can compete with the current income of longer-term Treasury notes “Favorable government regulations, coupled with the introduction of new and sophisticated products, and growing demand for synthetic biology, should keep driving the biotech industry’s…
The author of today’s article advises that “before investing in a biotech company, it’s essential to look at the financial opportunity offered by its current lineup of products (or most promising pipeline candidates), both in the short and long run.” With that, they proceed to highlight two biotech stocks that could be top picks right now based on the great…
While the biotech industry’s near-term potential is largely tied to the development of treatments for COVID-19, the author of today’s article notes that “The sector’s long-term potential remains solid due to the aging population and the rising cost of healthcare.” Against this backdrop, they proceed to highlight two biotech stocks that Wall Street analysts expect will see significant gains of…
At the mid-year point of 2021, what are the nation’s leading newsletter advisors’ favorite investment ideas for the remainder of the year? Today’s article reviews some of their top-performing picks from the beginning of the year and asks them for their mid-year updates. For ideas spanning biotech, cryptocurrency, electric vehicles, space exploration and more, CLICK HERE.
The clinical-stage biotech featured in today’s article, focused on developing treatments for fibrosis, cancer and other related diseases, has gained 18.7% over the past month. In order to determine whether it can continue its ascension and become a winner in the biotech industry, the author takes a look at the factors that could influence its performance in the coming months.…
Although a controversial decision, the FDA has approved Biogen’s Alzheimer’s drug, Aduhelm – and the decision caused Biogen’s stock to surge more than 60% in one day. On the heels of this, and with novel drug approvals on the rise, the contributors to today’s article discuss Biogen’s approval “and how ‘novel’ drugs can give biotech stocks a leg up ……